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Summary
14 patients with lepromatous leprosy received twice daily injections of 10 Wg recombinant
interleukin 2 (rIL2), by the intradermal route, in the skin of the back for 8 d (total dose, 160
P,g). Lymphokine administration was accomplished without drug toxicity, or the development
of acute nerve damage. The majority ofpatients developed nontender axillary lymphadenopathy
during the course of treatment. Local injection sites showed progressively larger zones of induration,
peaking at 24 h and persisting for many days. Early 12-h reactions were of a macular, erythematous
nature and exhibited an increasingly striking diurnal variation. The morning injection sites were
three- to fourfold larger in diameter than those placed in the evening (9 am to 9 pm). Systemic
manifestations of intradermal rIL2 administration were noted. Peripheral blood T cells, including
CD4+ and CD8+ phenotypes, increased 2-2.5-fold and NK cells increased sixfold. Elevations
in [3H]TdR incorporation into peripheral blood mononuclear cells occurred to a variety of
mycobacterial antigens, but not to those ofMycobacterium leprae. Within 2 wk, biopsies at sites
far removed from the back showed increased infiltration of mononuclear cells in 12 of 14 patients.
Immunocytochemistry revealed the presence of newly emigrated CD4+ T cells, monocytes, and
dermal CD1+ Langerhans cells. Endothelial cells of small dermal vessels expressed major
histocompatibility complex class II determinants on their surface. Transmission electron microscopy
of these specimens revealed markedly enlarged endothelial cells with many surface projections
extending into the lumen as well as extravasating lymphoid cells. The numbers of acid-fast M.
leprae in the peripheral sites were examined by slit smear and in biopsies of matched leprosy
lesions taken before and after IL-2 administration. Within 2 mo, slit smears showed a 0.5 log
or greater reduction in 12 of 14 patients, with a mean for all patients tested of 0.5 log units.
Biopsy specimens showed a 1 log unit or greater reduction in the bacterial index (B.I.) in 6
of 14 patients. Historical controls in this Nepalese population showed a 0.5 log unit reduction
after multidrug therapy over a period of 12 mo. Thus, after 8 d of IL2 injections, a fivefold
reduction in B.I. was observed during the first 2 mo of the study. Antibody levels against M.
leprae phenolic glycolipid 1 (PGL1) and lipoarabinomanan B were markedly elevated after IL-2
injections, while PGL1 antigen levels were reduced. We conclude that the administration of
rIL2 has had a significant effect in decreasing the totalbody burden ofM. leprae. This is accomplished
by the influx ofmononuclear leukocytes from the circulation, the enhancement ofcell-mediated
immunity, and the degradation ofleprosy bacilli. This occurs much more rapidly compared with
multidrug chemotherapy alone.
atients with lepromatous leprosy lack detectable cellular
￿
anergy is specific, and a vigorous cell-mediated response may
immunity directed against Mycobacterium leprae. This
￿
occur to other mycobacterial species, indicating they have all
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hypersensitivity (DTH)l reaction .
During the course of studies designed to dissect the var-
ious aspects of cell-mediated immunity, we discovered that
theintradermal administration of 10-25 jig of thelymphokine
IL2 will stimulatea reaction indistinguishablefrom an antigen-
initiatedDTH response (1-4), having the hallmarks: (a) in-
duration anderythema at the site ; (b) extensive and prolonged
dermal infiltration by T cells, monocytes, and Langerhans
cells ; (c) high CD4+/CD8+ T cell ratios in the emigratory
population ; (d) the absenceofinfiltration by granulocytic ele-
ments; (e) differentiation of mononuclear phagocytes to
epithelioidand giant cells ; (f) enhanced growth ofoverlying
keratinocytes and the induction of their MHC class II an-
tigens and IP-10 synthesis; (g) the generation of circulating
antigen-specific and -nonspecific cytotoxic effector cells; (h)
thedestruction of parasitized macrophages; (i) the killing and
clearance ofM . leprae .
When administered to patients with lepromatous leprosy,
a single intradermal injectionof 10-25 hg rIL2reconstitutes
the local cell-mediated reaction leading to the destruction of
M . leprae in the cutaneous site (5) . IL-2 inoculation also en-
hanced the responsiveness of circulating lymphocytes to an-
tigens to which the patient had previously been sensitized
(6). In addition, the level of antigen-specific T cell as well
as nonselective lymphokine activated killer (LAK) cell cyto-
toxicity against susceptible cell line targets andhuman mono-
cytes was increased (7).
These encouraging results, obtained with one to three in-
jections in the local dermal milieu, prompted us to extend
these studies to a multiple dose regimen. After a total dose
of 160hg of rIIT2, administered at 10-lAg injections each 12 h
for 8 d (16 injections), the systemic cell-mediated immune
response of lepromatous.leprosy patients is enhanced resulting
in the reduction of the total body burden of leprosy bacilli .
Materials and Methods
Patient Population.
￿
14 patients, 12-56 yr old, 10 with a clinical
diagnosis of polar lepromatous leprosy (LL), two with subpolar
lepromatous leprosy (SLL), and two with borderline lepromatous
leprosy (BL) (8), were selected for intradermal administration of
rIIL2 (Cetus Corp ., Emeryville, CA) (see Table 1) . Patients were
included in thestudy if they were diagnosed as LL/BL, hada bac-
terial index (B.I.) (at diagnosis) by slit smear of 3+ or higher, and
had received multidrug therapy (MDT) for no longer than 6 mo .
Patients were hospitalized at TheAnandaban Leprosy Mission Hos-
pital, Kathmandu, Nepal . Leprosy patients in reaction or on ste-
roid treatmentwere excluded from the study. Patients were informed
of the nature of the study and written consent was obtained from
all participants .
Patients hadbeen treated from 1 to 6 mo, and had receivedMDT
1 Abbreviations used in this paper : BCG, M . bovis Bacillus Calmette-Guerin;
B.I ., bacterial index; BL, borderline lepromatous leprosy; DTH, delayed-
type hypersensitivity ; LAK, lymphokine activated killer cell ; LAM-B,
lipoarabinomananB; LL, lepromatous leprosy ; MDT, multidrug therapy;
PGL1, phenolic glycolipid 1; PPD, purified protein derivative; SLL, subpolar
lepromatous leprosy.
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with 2 wk of supervised Rifampin (600 mg/d) followed by pulse
therapy with Rifampin (600 mg/mo), Dapsone (100 mg/d), and
clofazamine (50mg/d and300 mg/mo). One patient received only
Dapsone (100 mg/d) for 2 yr.
After patients were admitted, routine laboratory tests were per-
formed on blood and urine . Ageneral clinical and neurological exam
was conducted . These were repeated during and at the end ofthe
study. All chemotherapy wascontinuedduring the trial. Slit smears
taken from the same six sites including a lesion in each patient
were obtained for B.I . evaluation andperformed at the time of di-
agnosis . Patients were retested a day or two before 11,2 injection
and at intervals thereafter. 30 historical controls were selected and
evaluated for their rate ofreduction inB.I . during 24mo of therapy.
The controls were age and sex matched, clinically matched, and
had a mean ± S.D . B.I . at diagnosis of 3.6 ± 1.2 (range, 3-5+) .
Since all patients in the studyhadbeen treated (MDT) for at least
1 mo (mean, 4 mo), the rate ofreduction in B.I . for the historical
controls was calculated from 1 to 24 mo of MDT Starting after
the initial 1 or 3mo ofMDT(which includes intensive dailyMDT
for the first 2 wk) a meanB.I . reduction of 0.6 or0.5, respectively,
log reduction per 12 mo of therapywasobserved (for linear regres-
sion analysis for the best fit for all points plotted, see Fig. 7 inset) .
11,2 Administration.
￿
Human rIIL2 (1.8 x 107 IU/mg protein)
was transported and stored at 4°C until used . The lyophilized IL-2
was reconstituted in pyrogen-free sterile water and diluted in 5%
dextrose to a concentration of 100 Fag/ml, and used within 2 h
of reconstitution . Patients received a dose of 10 gg r1L2 at 12-h
intervals into apparently normal skin of theback on alternate sides.
Local erythema and induration of the injected site were evaluated
twice daily.
Histopathology and Enumeration ofBacilli.
￿
Biopsies (wedge shaped,
1cm in length) ofmatched, distal lepromatous lesions not injected
with IL-2 and not in areas within the lymphatic drainage of in-
jected sites were taken before, 5-13 d after the first IL2 injection,
and6 mo later. The biopsies taken before and 6mo after 11,2 . injec-
tion were removedfrom the same lesion, andthe 5-13-day biopsy
was taken from another clinically matched lesion . In addition, a
biopsy was taken from an area of the back not injected with IL-2
but within thelymphatic drainage of injected sites. Biopsies were
cut into three parts and processed for evaluation . A part of each
biopsy was fixed in 10% neutral buffered formalin overnight, em-
bedded in paraffin, sectioned, and stained with hematoxylin and
eosin for histological diagnosis and with acid-fast staining for
enumeration ofM . leprae . A logarithmic index ofbacilli in the bi-
opsies (9, 10) was used to express bacterial numbers in sites ob-
tained before, during, and after IL-2 injection .
Immunohistology .
￿
Biopsy specimenswere fixed in paraformalde-
hyde (3%), lysine (0.075 M), and sodium-m-peroxdate (0.01 M)
in PBS(PLP) for3h at4°C as described (11) . This fixative preserves
structural details without destroying the serological reactivity of
the cell surface . The biopsies were washed in PBS containing su-
crose (10%) and digitonin (5 x 10-5 M) and then serially sus-
pended in graded solutions of sucrose (15-25%) . The tissue was
stored in PBS with sucrose/glycerol (25% and 5%, respectively)
for transport back to the U.S. until frozen .
Biopsies were embedded in OCT compound and frozen at
-20°C; 6-8-ttm sections were cut on a cryostat and applied to
gelatin-coated multi-well slides (Carlson Scientific Inc., Peotone,
IL). The sections were dried overnight at 37°C, rehydrated in PBS,
and incubated with mouse mAbs followed by biotinylated horse
anti-mouse Ig andthen avidin-biotin peroxidase complexes (Vector
Laboratories, Inc ., Burlingame, CA) . The reaction product wasde-" Slit smears at six sites.
t According to the Ridley Jopling classification, see Materials and Methods.
S MDT in months.
11 No. of months of pulse NOT = monthly Rifampicin (600 mg) and clofazamine (300 mg) + daily DDS (100 mg) and Clofazamine (50 mg).
1 Intensive daily 600 jig of Rifampicin for 14 d plus MDT for numbers of months indicated.
'" 24 mo of DDS (100 mg/d only).
veloped with 0.8 mg/ml 3-amino-9-ethylcarbazole and 0.015%
H202. Sections were counterstained with hematoxylin.
Monoclonal and Polyclonal Antibodiesfor Tissue Staining.
￿
Mouse
mAbs were used for the identification of specific cell types. Leu-1,
Leu-2a, and Leu-3a (12, 13) (anti-CD5, -CD4, and -CD8, antiT
cells) and Leu-M5 (anti-CD11c, anti-monoryte/macrophage) (14)
were obtained from Becton Dickinson&Co. (MountainView, CA).
OKT6 (15) (anti-CD1, anti-Langerhans cells) was obtained from
OrthoDiagnostic Systems, Inc. (Westwood, MA). Antibody 9.3F10
(anti-MHC class II antigen) was produced in this laboratory (16).
Rabbit anti-y IP-10 antibodies were produced in this laboratory (17).
Electron Microscopy.
￿
Apart ofeach biopsy wasprocessedfortrans-
mission EM studies. Biopsies were fixed in 2.5% glutaraldehyde
in 0.1 M cacodylate buffer with 0.1 M sucrose, pH 7.4, for 16 h
at 4°C, postfixed in 2% 0504 for 1 h at 4°C, stained in block
for 1 h with uranyl acetate in 70% ethanol, dehydrated in incre-
ments with ethanol, and embedded in epon blocks. Sections were
stained with lead citrate, and examined with a transmission elec-
tron microscope (JEM 1000X;Jeol USA, Peabody, MA). At least
200 cells from each patient were examined and photographed on
Kodak electron image film.
PBMC Phenotyping.
￿
Indirect immunofluorescent staining was
used to identify blood mononuclear cell types and their subsets.
Blood mononuclear cells (2-4 x 104 cells) were allowed to settle
on poly-L-lysine (50 Wg/ml; Sigma Chemical Co., St. Louis, MO,
USA)-coated multi-well slides (Carlson Scientific Inc.) for 30-60
min on ice, quenched with 1% BSA, and incubated for 60 min
with hybridoma(obtained from Dr. Robert Evans, Sloan-Kettering
Memorial Hospital, New York) supernatants containing mAbs
directed against CD3 (Leu-4), CD4 (Leu-3), and CD8 (Leu-2);
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purified mAbs (Becton Dickinson & Co.) directed against CD16
(Leu-11b) and CD20 (Leu-16); or supernatants containing mAb
directed against CD14 (3C10) (16). Immunofluorescent staining
was carried out using biotinylated horse anti-mouse IgG (heavy
and light chains), and fluorescein-avidin (obtained from Vector
Laboratories, Inc.).
Cell were also analyzed by flow cytometry. The buffer used
throughout consisted of PBS containing 2% FCS, 0.1% NaN3,
and normal human IgG (1 /AM) to block Fc receptor binding. PE-
conjugated mAbs reactive with CD3, CD4, CD8, and CD56
(NKH1) were obtained from Coulter Clone (Hialeah, FL). FITC-
conjugated mAbs reactive with the IL-2R p55 chain were from
Coulter Clone and for the II.2R p75 chain (18) (TU27) were
from Dr. Kazuo Sugamura (TohokuUniversity, Sendai,Japan). The
PE-conjugated and I1r2Rp55 mAbs were used at a final dilution
of 1:20, and theanti-111,2R. p75 wasdiluted 1:100. Cellswere stained
at 4°Cfor1 h with two sets of mAbs to reveal nonspecific binding.
One set of cells were stained in the presence of a 100-fold excess
of unconjugated mAbs, and onesetwithout unconjugated mAbs.
After incubation, the cells were centrifuged, the supernatant re-
moved, and 1 ml of PBS + 0.4% paraformaldehyde was added.
Thecells were stored at 4°C untilanalyzedby flow cytometryusing
a cytometer (Ortho Diagnostic Systems, Inc., Westwood, MA).
At least2,000cells were analyzed in each preparation, and theper-
centage of positively stained cells was calculated.
Lymphoproliferative Assays.
￿
PBMC were prepared by Ficoll-Paque
density separation andused to determineresponses to thefollowing
stimuli: M. leprae (106 to 108particles/ml) (batch CD-94, obtained
from Dr. R. J. WRees, Mill Hill, UK, through the WHO Im-
munology of Leprosy Programme); M. bovis Bacillus Calmette-
Table 1. Patient Information and Clinical Status
Clinical Day of post-IL-2
Patient no. Age Sex B.I. at diagnosis diagnosist MDT PUS blood and biopsy
yr mo
1 56 M 4.0 LL 611 13
2 35 M 4.25 LL 1 13
3 48 M 5.25 LL 6 9
4 35 M 5.0 LL 41 9
5 36 M 4.5 SLL 6 9
6 46 M 4.25 SLL 5 9
7 40 M 5.25 LL 61 5
8 45 M 3.75 BL 5 5
9 12 M 4.5 LL 11 5
10 33 M 4.0 LL 31 5
11 38 F 4.8 LL 4 5
12 55 F 4.0 LL 1 13
13 40 F 4.0 BL 61 13
14 45 F 3.0 LL 24" 13Guerin sonicate (BCG; 1-10,ug/ml) (19) (Commonwealth Serum
Laboratory, Melbourne, Australia); purified protein derivative of
tuberculin (PPD; 10,ug/ml) (Staten Serum Institute, Copenhagen,
Denmark); PHA (a 1:200 dilution) (Sigma Poole, Dorset, UK).
The 65- and 70-kD proteins ofBCG (0.1-10hg/ml) were affinity
purified from BCG sonicatesusing the mAbs L22 and L7, respec-
tively, as described(20, 21), andobtained from the Clinical Immu-
nology Research Center, University of Sydney, Sydney, Australia.
The 18-kD recombinant protein of M. leprae (0.1-10 Fcg/ml) (22)
was obtained from Dr. Watson, Auckland University School of
Medicine, Auckland, New Zealand. The cells were incubated in
RPMI 1640 containing penicillin (100 U/ml) (Gibco Laboratories,
Grand Island, NY), 2 mM glutamine supplement (Gibco Labora-
tories), and 10% normal human A' serum in a final volume of
220 tt1. After 6 d of incubation, the cells were pulsed with 1 1eCi
['H]thymidine (Amersham International, Amersham, Bucks,
UK). Afterdrying, thefilters were prepared forliquid scintillation
counting in an liquid scintillation analyzer (1500; Packard Instru-
ment Co., Inc., Downers Grove, IL).
Evaluation ofM . leprae Phenolic Glycolipid-1 levels in Patient Serum.
Phenolic glycolipid 1(PGL1) ofM. leprae levels in serum of leproma-
tous patients wasevaluatedby an ELISA describedby Cho et al. (23).
Evaluation ofAnti-M. leprae Ig Levels.
￿
IgManti-PG1A antibodies
were measured by ELISA using the glycoconjugate disaccharide-
BSA (dBSA; provided by IMMLEP, World Health Organization)
as described (24).
IgG antilipoarabinomannan B (LAM-B) antibodies were mea-
sured by ELISA using M. tuberculosis LAM-B as antigen (provided
by Dr.P. J. Brennan, Colorado StateUniversity, Fort Collins, CO)
using the conditions described previously (24).
Results
Experimental Design
There were twomajorconsiderations in the design of this
experiment. The first was to uselow, nontoxic doses of rIL2
and to study the local and systemic influences of the lym-
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￿
The effect of increasing the dose of rIL2 on the extent of
induration. With an increase in the number of previous 11,2 injections,
a larger area of induration is observed at the 24-h time point. However,
thekinetics ofthedecrudescence of thereaction from 48 hwere notaffected
by the dose of 11,2 administered.
phokine in considerable depth. The second was to use the
intradermal routeto allow us an additional parameterfor the
evaluation of theintensityof the localcell-mediatedimmune
response. The lymphokine was administered twice daily (9
am and 9 pm) at doses of 10 Lug, for a total dose of 160 NAg
in 8 d. Before, during, and at time intervals up to 6 mo after
the completion of the schedule, samplesof peripheral blood,
skin biopsies, slit smears, andclinical analyses were carried out.
The Local Response to rII,2
Thelymphokine was administered in a set pattern on the
back starting in the paravertebral area at the level of T2 and
placed -4 cm on either side of the spinous processes. The
9 am injection was given on the left side and the 9 pm on
the right. Injections were then given in adescending fashion
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Figure 1.
￿
Thelocal response to rIL2
injections 12 (A), 24 (B), 36 (C), and
48 h(D)afterlymphokine administra-
tion. Themean areas of erythema (A)
and induration (B-D) for all patients
tested in mm2 ± 1 SD of the mean
(B-D) are shown. At 12 h, a clear di-
urnal variation was observed with a
higher response at sites injected at 9am.
An enhancement in the extent of the
response ofall sites initially injected at
9 am (arrows) was observed with re-
peated injection. Sites injected at 9 pm
gave similar responses throughout the
study (A). Thediurnal variation andthe
enhancement in theextent oftheindu-
ration with progressive injections are
prominent at 24 h(B) andstillobserved
by 36 h (C). These changes are no
longer evident by 48 hafterlymphokine
injection (D).
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￿
Light microscope micrographs demonstrating the effect of rIIL2 administration on the cellular composition ofcutaneous lepromatous leprosy
lesions not injected with 11,2 and not from areas within the lymphatic drainage of the injected sites. H+E-stained sections of matched pre-IL2 (A)
andpost-11,2 (B) skin biopsies revealed an increase in cellularity (mostly lymphoid cells) (arrows) after lymphokine injection. Immunohistological staining
for CD3+ T cells of matched pre-IL2 (C) and post-IL2 (D) biopsy sites demonstrated a clear 11,2-induced T cell accumulation in the lesions . Im-
munohistological staining for CDl+ Langerhans cells revealed an 114-induced dermal perivascular accumulation of these cells in the post-rII.2 biopsies
(arrows) (E and F) . The arrow heads inE mark the epidermis . A and B, patient no . 8, x 50 ; C and D, patient no . 11, and E and F, patient no . 6, x 200 .
ending at a site in line with the upper pelvis . The local reac-
tions were never overlapping.
The 12-h Site
￿
The initial injection of 10 jig 11,2 gave an
area of induration of ti 14 mm in diameter and resembled
in every way results obtained in a prior study (5) . With
repeated injections interesting effects were observed in both
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the intensity and temporal nature of the local reaction . One
of the first to be noted was the striking enhancement in the
extent of the response at the 12-h time period (Fig. 1 A) .
This reaction was characterized by the presence ofan erythema-
tous, raised, macular lesion with irregular margins and ap-
peared to have a vascular component . At the time ofthe firstTable 2.
￿
Total and Deferential White Cell Counts Before, During and After the Administration of IL-2
Mononuclears
Neutrophils
Eosinophils
Total white blood cells
￿
7,875
Data represent number of cells per mm3 of blood.
" 10 i4g HL-2 administered every 12 h intradermally for 8 d for a total dose of 160 Wg.
Results are means of bloods obtained from 14 patients ± 1 SEM.
evaluation (12 h), it covered an area of about twice the firm
zone ofinduration found at the 24-h reading (Fig. 1 B). With
repeated injections, these sites were very much larger with
long finger-like extensions extending much beyond the central
zone. It became apparent by the end of the series that these
larger responses were always the result of the 9 am injection
and were enhanced after the fifthinjection. This striking di-
urnal variation in the 12-h response is seen in Fig. 1 A .
Indurated Sites.
￿
At 24 h and for several days later, the in-
jected siteswere firmly indurated. The largest area ofindura-
tion occurred at 24 h, in keeping with our earlier results.
Fig. 1, B-D illustrates the sites read at 24, 36, and 48 h. It
is clear that with repeated IL-2 injections the maximum
zone of induration at 24 h increased by twofold. With the
passage of time, both the diurnal variation and localenhance-
ment of induration were less evident. This was the result of
the temporal response seen in Fig. 2. Although the maximum
zone of induration was markedly affected by increasing the
dose of 11,2, the subsequent decrudescence of the reaction
occurred with similar kinetics so that by 72 h little difference
was noted in the areas of induration.
From our previous studies we know that the 24-h site is
already heavily infiltrated with newly emigrated T cells largely
of the CD4+ phenotype (5).
Local Skin Lesions.
￿
By the end ofthe course of 11,2 injec-
tion, two patients with extensive skin lesions over the entire
back showed flattening of the lesions in the central region
ofthe back, whereas more peripheral lesions were unaffected.
The Systemic Effects of rIL2
Clinical Course.
￿
Daily evaluations of the clinical state of
patients during and after the 8-d course of 11,2 were per-
formed. Other than mild pruritus, the indurated sites on the
back gave no discomfort. A few patients developed a low
grade fever (0.6-1.0°C) during the course of the injections,
lasting a day or so without malaise. At times after the third
day of treatment, nontender axillary lymphodenopathy was
present in the majority of patients. Detailed examination of
nerve conduction was performed each day by a trained ob-
server. There was no evidence of any additional neural in-
Days after IL-2 injection"
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8,278
￿
8,071
￿
9,364
volvement either during or after the study. Neither weight
gain nor edema were noted. One patient developed significant
fever with swelling and erythema of skin lesions after 13 in-
jections. There was no neural involvement. An acute infec-
tion, pharyngitis, had also developed at this time. The rIIr2
was stopped and the cutaneous reversal reaction resolved with
corticosteroids.
Peripheral Blood Cells and their Phenotypes.
￿
The total and
differential cell counts of peripheral blood obtained at times
up to 13 d after the initiation of 11,2 injections are shown
in Table 2. A small enhancement in totalwhitecells was noted,
the majority of which was contributed by a 1.5-fold increase
in mononuclear cells and a twofold increase in eosinophils.
Neutrophil levels remained unchanged.
The phenotype of PBMC during this same period is shown
in Table 3. The number of B lymphocytes and monocytes
remained essentially unchanged. T cell numbers increased by
about two-fold, with the largest increment being evident in
the CD4+ series. It was noteworthy that the number of NK
cells increased sixfold starting from subnormal, initial levels.
The low numbers of IL2R bearing cells (the p55 and p75
chains) did not increase.
In VitroLymphocyteFunction.
￿
The responses ofPBMC to
a variety of antigens expressed on whole M. leprae and BCG
as well as proteins separated from these organisms is seen in
Table 4. Before IL2 injections, all but one patient failed to
respond to M. leprae and its 18-kD protein. This nonreac-
tivity persisted in samples collected during and immediately
after the entire course of IL2. One patient demonstrated a
positive proliferative response to whole M. leprae immedi-
ately after the course of rIL2 injections, but this reverted to
negative in the assays at 2 and 6 mo. By comparison, most
patients initially responded to whole BCG, PPD, and the 65-
and 70-kD proteins of BCG. After IL2 injections, the cells
from most patients showed an enhanced response to these
antigens by factors oftwo- to fourfold. Therefore, it appeared
that 11,2 enhanced lymphocyte reactivity to antigens that the
patients had been previously sensitized to, but did not modify
the selective anergy to M. leprae.
The cytotoxic activities ofNK and LAK cells before, during,
and after IL2 injections were not appreciably altered.
0 5 9 13
2,349 ± 253 2,669 ± 285 2,952 ± 278 3,552 ± 213
4,800 ± 425 4,271 ± 429 4,051 ± 434 4,579 ± 632
634 ± 111 1,314 ± 216 1,041 ± 168 1,472 ± 509Table 3.
￿
The Phenotype and Numbers of PBMC Before, During, and After rIL-2 Administration
Data represent number of cells per mm3 of blood.
" 10 Ftg HL-2 administered every 12 h intradermally for 8 d for a total dose of 160 pg.
t Results are means of bloods obtained from the numbers of patients in parenthesis ± 1 SEM. The pre-IL-2 values for the three different groups
(days 5, 9, and 13) were not significantly different from the mean for all 14 patients.
Table 4.
￿
The Prolferative Response of PBMC to Mycobacterial Antigens Before and After rIL-2 Injection
13H]TdR incorporation was considered + when the stimulation index was >10, ± when the stimulation index was 6-10, and - when <5.
t Activity was calculated as percent of [3H]TdR incorporation 5-13 d after initiation of IL-2 injection (see Table 1) evaluated as stimulation index
relative to the pre-IL-2 response.
5 A transient enhancement in proliferative response to wholeM. leprae wasobserved 1 d afterthe last IL-2 injection (9 d). Responsiveness was nega-
tive when the patient was tested 2 mo later.
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Days after IL-2 injection"
Patient no.
M.
Whole
leprae
18 kD
Pre-IL-2
Whole
proliferation"'
BCG
65 kD 70 kD PPD
M .
Whole
leprae
18 kD
Post-IL-2 percent
Whole
activity#
BCG
65 kD 70 kD PPD
1 - - + + + + - - 317 270 152 155
3 - - + + + + 2995 - NT 144 377 NT
6 - - + + + + - 400 381 514 314 211
8 - - + + + + - - 383 374 253 234
9 - - + + + + - - 242 219 34 204
10 - - ± ± - _ - - 155 189 - -
11 - - + + + + - - 163 731 280 186
13 - - + + + + - - 155 413 235 187
2 - - + + + + - - 76 77 61 66
5 - - + + + + - - 33 31 48 157
14 + - + + + + 93 - 50 78 94 129
4
7
Surface antigen
(cell type)
0
(14)
5
(5)
9
(4)
13
(5)t
CD 3
(pan T) 910 ± 129 1,196 ± 266 1,291 ± 124 1,946 ± 615
CD 4
(T helper) 483 ± 155 601 ± 154 863 ± 125 1,252 ± 299
CD 8
(T cytotoxic) 440 ± 116 496 ± 242 929 ± 411 996 ± 88
CD 20
(B cells) 317 ± 103 387 ± 186 256 ± 84 542 ± 96
CD 14
(macrophages) 352 ± 115 335 ± 49 417 ± 84 386 ± 94
CD 56
(NK cells) 55 ± 9 137 ± 34 324 ± 81 460 ± 35
MHC class II 382 ± 129 688 ± 163 507 ± 126 824 ± 220Table 5.
￿
Elect ofIL-2 Administration on the Histology, Cellular Phenotype and, M. leprae Load in the Skin
T cell numberswere evaluated by direct microscopic counting ofH+ E-stained and immunohistological stained sections. (+). Therelative numbers
of T cells were at least doubled by both methods of evaluation; (±) slight enhancement in T cell numbers was observed; (-) no change in T cell
numbers was observed.
t 6-mo post-IL-2 injection biopsy taken from a site on the back distal to the IL-2 injection area.
SBiopsies that showed upgrading and the presence of epithelioid and multinucleated giant cells.
11 T cell numbers enhanced by H+E staining but not by immunohistological evaluation.
Immunocytochemistry and Histopathology ofPeripheral Sites.
We have previously described the local response to IL2 in-
oculation, includingthe numbers andphenotypes ofemigra-
tory cell populations (5). In this study, we focusedon changes
at matching skin sites distal from the foci of IL -2 injections
(sites not injected with nor in the area of drainage of IL2).
Within 13 d after the administration of rIL2, skin biop-
sies of 12 of 14 patients demonstrated an increase in lym-
phoid cells at peripheral sites (Table 5 and Fig. 3, A and B) .
By mAb analysis, the emigratory cells consisted largely of
T lymphocytes, and CD4+ T cells were present in large
numbers (Fig. 3, C and D). This body-wide infiltrate also
contained newly arrived monocytes and macrophages with
the presence of differentiated epithelioid cells and mul-
tinucleated giant cells. Of interest was the increase in the
1000
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number of CD1-positive Langerhans cells in the dermal
infiltrate (Fig. 3, E andF) in a perivascular localization. En-
dothelial cells of the skin vasculature expressed MHC class
II antigens on their surface (data not shown).
Transmission Electron Microscopy of Peripheral Sites.
￿
Glu-
taraldehyde-fixed specimens of skin biopsies of distal lesions
were taken before and after IL2 administration. It is clear
from Fig. 4 that the cellularity of the post-IL2 siteswascon-
siderably increased with a preponderance of lymphoid cells.
This is in keeping with the H+E-stained sections illustrated
in Fig. 3. Parasitized macrophages and foam cells were clearly
damaged and fragmented.
An unusualfindingwas made upon closer examination of
the endothelial cells of small dermal vessels. These are seen
in more detail in Fig. 5. The endothelium of pre-IL2 sites
Figure 4.
￿
Transmission electron micrographs demonstratingtheeffect of rIIL2administration on thecellular response in lesions oflepromatous leprosy
patients (see above). (A) Pre-11,2 site containing a small blood vessel with an erythrocyte (E) and a lymphocyte (Ly). A loose perivascular infiltrate
of inflammatory cells is observed (arrows). The endothelium (Endo) appears normal. (B Pre-IL2 site from the same biopsy as A. The inflammatory
infiltrate is composed predominantly of parasitized foamy macrophages. Three such cells with their nuclei (Nu) can be seen. (C) Post-IL2 site from
a matchedlesion obtained from the same patient as in A and B. The cellularity of the lesion is much higher. More lymphoid cells are present (arrows)
and some of themacrophages have a more epithelioid appearance. (D) Pre-IL-2 site containing macrophages with intravacuolar M. leprae (arrows). (E)
Post-IL2 injection site showingasmalldermal bloodvessel identified by erythrocytes (E)with extensive vacuolizationof theendothelium. Theperivas-
cularphagocytes appear damagedanddisintegrated (arrows). (F) Post-L2 injectionsite showingdamagedmacrophages (arrow heads) andintact lymphoid
cells (arrows). A-C, patient no. 12, D-F, patient no. 8. A and B, x5,000; C and D, x3,000; E, x4,000; F, x3,200.
Patient no.
Histological diagnosis
Pre-IL-2 2 mo 6 mo
Enhanced T
cell numbers"
5-13 d
Slit smears
(six sites)
Pre-IL-2 2 mo 6 mo Pre-IL-2
Histological biopsies
5-13 d 6 mo 6 mo DBt
B. L B. 1.
1 LL BLS LL 4.0 4.1 3.3 4+ 4+ 4+ 3+
2 LL LL LL + 3.8 3.8 3.9 5+ 5+ 4+ 4+
3 LL LL LL - 4.3 3.6 4.3 5+ 5+ 6+ 5+
4 LL LL BL +/-11 4.3 3.5 3.7 5+ 5+ 4+ 1+
5 LL LL LL - 4.3 3.5 4.0 5+ 5+ 5+ 4+
6 LL LL SLL, + 3.8 3.2 4.0 5 + 5 + 4+ 4+
7 LL BLS ND + 5.0 4.5 ND 6 + 5 + 4+ 4+
8 LL BLS BL + 3.7 3.5 3.0 5 + 4 + 4+ 4+
9 LL LL LL ± 4.7 4.3 3.8 5+ 6+ 5+ 1+
10 BL BTS ND +/- ~~ 2.6 2.2 ND 2+ 0 ND ND
11 LL LL LL + 4.7 ND 4.2 6+ 5 + 6+ 5 +
12 BL BTS negative + 3.3 2.8 1.4 3 + 1+ 0+ 0+
13 LL LL BL +/-~~ 3.5 ND 2.6 6+ 5+ 5+ ND
14 LL LL ND + 3.6 3.1 ND 2+ 2+ ND ND1001
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￿
The reduction in bacterial index evaluated from slit smears
of the same six sites afterr1L2 injection. The B.I. ofpatients wasevalu-
ated before (0), at 2, and at 6 mo after IIL2 injection. The mean ± 1
SEMis shownfor all patients tested at each time point. Theinsert shows
the B.I. reductionfor30 matchedhistorical controls. A0.6 logreduction
is observed during 12 mo of therapy (see Materials and Methods).
is rather flat and contains numerous small endocytic vessels
in keeping with the usual structure of capillaries (Fig. 5, A-C).
After IL2 injection, the endothelium became thickened with
many long projections extending into the lumen, and larger
cytoplasmic vacuoles were evident (Fig. 5, D-F). Emigra-
tory cells were observed between endothelial cells, and the
lumen contained larger numbers ofmononuclear leukocytes.
The basement membrane of the vessels was thickened and
had an edematous appearance. Extravascular sites were essen-
tially normal other than their increased cellularity, and a
striking selective destruction of foam cells and other mono-
nuclear phagocytes.
The Fate ofM. Leprae.
￿
For slit smear analysis, the same,
six sites were tested at various time points before and after
1162 injection, and theB.I. of the sites were reviewed by trained
technical staff. The composite data on 14 patients is given
in Table 5. Upon slit smear analysis, 7 of 12 patients evalu-
ated demonstrated 0.5 log or greater reduction in B.I. at 2 mo.
A mean reduction of 0.5 log units for all patients tested at
Figure 5.
￿
Transmission electron micrograph demonstrating theeffect of rII.2 administration on the small blood vessels of lepromatous lesions (see
Fig. 4). The endothelial surface forming the lumen (Lu) of the pre-IL2 sites (A-C) is relatively flat and regular (arrows in A and C) and contains
many small, regularendocytic vesicles. The underlying collagen (coil) is normal. In the post-11,2 lesions (D-F), the endothelium is swollen with long
projections into thevessel lumen(arrows) andlargeirregularvacuoles. Theunderlying basement membrane is thickened andedematous(colt) E-erythrocytes.
Thejunctions of thevasculature appear intact both before (B and C) and after (E) IL2 injection (curved arrow in B, C, andE). A, D, and F, patient
no. 11; B, C, and E, patient no. 14. A,
￿
x4,600; B,
￿
x9,000; C, x20,000; D,
￿
x6,600; E, x3,700; F,
￿
x11,000.
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2 mo was observed (Table 5 and Fig. 6). An additional 0.1
log units reduction in B.I. was noted from 2 to 6 mo, sug-
gesting that the effect of IIr2 injection on bacterial clearance
was almost immediate and required the continuous presence
of the lymphokine. Matched historical control BULL leprosy
patients, not injected with IL2, were evaluated for B.I. reduc-
tion during 24 mo of MITT These controls demonstrated
a 0.5-0.6 log unit reduction in B.I. during 12 mo of MDT
or 0.08-0.1 log units per 2 mo of therapy (Fig. 6). Thus,
consistent with these results from matched historical con-
trols, a five- to sixfold increase ofclearance was observed during
the 2 mo after only 8 d of IL2 injection.
For biopsy analysis, examination of peripheral skin biop-
sies was performed before IL2 injections, 5-13 d after the
initiation of IL2, and at 2 and 6 mo thereafter. These were
obtained from leprosy lesions not injected with IL2 and not
within the lymphatic drainage of the injected sites (primarily
the arms and legs). Coded slides were examined for histolog-
ical diagnosis, lymphocytic infiltrate, and bacillary indices by
two independent investigators.
Bacterial indices evaluated from biopsy sections showed a
1 log or greater reduction in 6 of 14 patients already at the
5-13-d time point (Table 5 and Fig. 7). 6 mo after the course
of IL2 injection, 7 of 12 patients showed B.I. reductions,
at peripheral sites not exposed directly to IL2 (Table 5, Fig.
8). Biopsy sites on the back showed a more striking decrease
in bacillaryload than elsewhere on the body. This zonal effect
may be related to the lymphatic drainage of the area and the
passage of a greater number of inflammatory cells from the
centrally located IL2 sites.
Antibody Titers against M. leprae Components.
￿
Serum levels
of PGIA were measured before and at various times after 11,2
injection. Antigen levels were high in the tested patients at
the start of the study. However, after the initiation of IL2
injection, a sharp reduction in the levels of antigen in the
serum was observed even within 2 wk of treatment. (Fig. 9 A).
Antibody titers against M. leprae PGL1 and the polysac-
charide antigen LAM-B were measured before and at various
times after IL2 injections. All but one of our Nepalese pa-
tients had been treated with a multidrug regimen for 1-6
mo, and the IgM PGLl levels had fallen from pretreatment
levels in some cases. 2 mo after IL2 injections, there was a
rise in the IgM anti-PGLl levels, and by 6 mo, the levels
were falling (Fig. 9 B). The IgG anti-LAM-B levels increased
about twofold only (data not shown) .
We suggest that the lymphokine-enhanced degradation and
clearance of bacilli reduces the amount ofM. leprae antigens
in the circulation. It also stimulates the synthesis ofantibodies
directed at mycobacterial cell wall carbohydrates and lipids.Figure 7 .
￿
Effect of 11,2 administration on theM leprae load in the lesions of lepromatous patients taken from sites not injected with IL2 and not
within areas of lymphatic drainage of the injected sites . High numbers of acid fast bacilli are seen is the pre-IL2 sites (arrows) (A and C) . A clear
reduction in the numbers of bacilli of matched site after IL2 injection is observed (arrows) (B and D, respectively) . A and B, patient no . 7; C and
D, patient no . 8 . (x400) (fite acid-fast stain) .
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Figure 8.
￿
The reduction inB.I . evalu-
ated from acid-fast stained sections of
biopsies after rIL2 injection. The B.I.
ofpatients was evaluated before (0) and
6 mo after the initiation of 11,2 injec-
tions . Biopsies were taken from lesions
in the periphery not injected with 11,2
and not in areas of11,2 drainage or sites
on the back not directly injected with
11,2 but possibly in areas of IL2 drain-
age. Each line represents a single patient.W
UJ
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Figure 9.
￿
The effect of 11,2 injection on the levels of PGIA antigen
(A) and on IgM levels against PGIA (B). Activity was evaluated in the
serum of patients before (0), 5-13 d, 2 mo, and 6 mo after start of 11,2
injection.
This limited trial of rIIr2 administered intradermally has
successfully modified the natural history of leprosy in the
majority of patients. Low doses of the lymphokine have had
clear systemic effects, including an elevation of the number
of circulating mononuclear cells, a generalized infiltration of
lymphocytes into the skin, and the subsequent rapid clear-
ance of M. leprae (fivefold increase in the rate of clearance)
as compared with the influence ofMDT alone. This occurred
in the absence of significant IL -2 toxicity, and without
precipitating an uncontrolled reactive state or additional pe-
ripheral neuropathy. Moreover, it has been achieved in an ac-
celerated time frame measured in weeks rather than in years.
Our findings indicate that rIL2 has enhanced the genera-
tion of a more vigorous cell-mediated immune response in
patients with lepromatous leprosy. This response has occurred
without indication that we have stimulated specific anti-
M. leprae cellular immunity, in that neither M. leprae-specific
T cell mitogenesis nor the generation of cytotoxic effector
cells to M. leprae antigen occurred. Even so, enhanced cel-
lularreactivity was characterized by the: progressively increased
zones of induration at the injection sites; generalized cuta-
neous infiltration with T cells, monocytes, and Langerhans
cells; a reduction in the bacillary index as determined by slit
smears and biopsies; and a reduction in the size of skin le-
sions. The elevation in antibodies against M. leprae products
is consistent with this interpretation and suggests a humoral
immune response to a new antigenic load released from the
tissues. In addition, the reduction in M. leprae PGL1 antigen
levels is consistent either with a systemic reduction in bacil-
lary load and/or the clearance of immune complexes.
The progressive increase in the zones ofinduration taking
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place during the course of 11,2 injections is the result of an
increased number of emigratorycells entering the sites. This
is in keeping with previous information on the relationship
between induration, the percentageofthe dermis infiltrated,
and the percentage ofT cells in IIr2 and antigen-driven reac-
tions (2, 5). In a manner yet to be determined, prior IL2
injections influence the intensity of the local emigratory re-
sponse. This may occur by sensitizing circulatory cells for
the recognition of the local site and/or by modifying the en-
dothelium of the local vasculature. As we observed, the en-
dothelium of small, dermal vessels is structurally altered and
expresses MHC determinants. This may promote the binding
and transmigration of intraluminal mononuclear cells and may
help explain the widespread influx of T cells into peripheral
sites. One must also consider rolesfor other IIr2-induced lym-
phokines and cytokines (e.g., IFN-'y) in generating , local
chemoattractants. We suspect that the efficacy of the emigra-
tory response is in part the result of the pre-existing infiltrates
that occur in the skin of lepromatous leprosy patients. Pre-
liminary observations in patients with a normal dermal milieu,
but receiving long-term IL2 therapy, show smaller numbers
of infiltrating cells (G. Ritz, personal communication). Fi-
nally, the 12-h responses are indicative of enhanced vascular
permeability and functional alterations in the endothelium.
The reduction in the number ofleprosy bacilli that occurs
in both local and peripheral sites requires the destruction of
aged, parasitized macrophages (3, 5). This process is associated
with the generation of effector cells that selectively recog-
nize infected mononuclear phagocytes and spare other ele-
ments of the cutaneous site. Since we cannot document the
enhancement ofM. leprae-specific cytotoxic T cells, it is likely
that cells with less selective recognition mechanisms may be
involved. These would include NK, LAK, and perhaps
y/S+ T cells as likely candidates for this mechanism (7, 25).
These findings are consistent with prior results from the anal-
ysis of the cellular composition of antigen-initiated DTH re-
sponses: by far, the vast majority of cells emigrating to the
site of antigen inoculation are not antigen-specific reactive
T cells. From the results of this study, it appears that IL2
or an 11r2-induced product can act as a chemotactic signal
for extravasation ofmononuclear leukocytes into the dermis,
where these probably mediate the antimicrobial response we
have observed.
These results support the conclusion that IL2 can reduce
the totalbody burden ofM. leprae when combined with mul-
tipledrug chemotherapy in patients with leprosy. This effect
appears to result from a controlled enhanced cell-mediated
response and may be applicable to a number of other chronic
infectious processes, including the opportunistic pathogens
of AIDS. The partial responses obtained after only 8 d sug-
gest that more prolonged administration of the lymphokine
would be beneficial and might even be curative. Whether
or not this form of immunotherapy will be applicable to a
larger segment of leprosy patients is unclear. However, it is
evident that a detailed analysis oflymphokine biology in man
is central to our ability to manipulate the immune response
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